Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to -$71000.0.

  • Xeris Biopharma Holdings' Cash from Investing Activities fell 10071.62% to -$71000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year decrease of 84.23%. This contributed to the annual value of $4.9 million for FY2024, which is 18132.91% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Cash from Investing Activities stood at -$71000.0, which was down 10071.62% from -$279000.0 recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Cash from Investing Activities registered a high of $36.6 million during Q4 2021, and its lowest value of -$44.0 million during Q1 2023.
  • In the last 5 years, Xeris Biopharma Holdings' Cash from Investing Activities had a median value of $9.2 million in 2022 and averaged $6.9 million.
  • In the last 5 years, Xeris Biopharma Holdings' Cash from Investing Activities skyrocketed by 40492.48% in 2021 and then plummeted by 75483.92% in 2023.
  • Xeris Biopharma Holdings' Cash from Investing Activities (Quarter) stood at $36.6 million in 2021, then tumbled by 74.95% to $9.2 million in 2022, then soared by 62.17% to $14.9 million in 2023, then crashed by 32.63% to $10.0 million in 2024, then plummeted by 100.71% to -$71000.0 in 2025.
  • Its Cash from Investing Activities stands at -$71000.0 for Q3 2025, versus -$279000.0 for Q2 2025 and -$13000.0 for Q1 2025.